方法：随即选择湿性年龄相关性黄斑变性207例207眼，所有病例均行玻璃体腔注射bevacizumab 1.5mg/0.06mL。于术后第1d； 1，4，12wk除了详细询问主诉，并进行常规视力(最佳矫正视力)、非接触眼压、裂隙灯显微镜、间接眼底镜等检查。

结果：治疗12wk后，视力改善的有效率为90.8%。术后出现眼痛伴异物感7例(3.4%)，眼睑皮肤瘙痒1例(0.5%)，结膜充血6例(2.9%)，球结膜下出血1例(0.5%)，术后眼压升高2眼(1.0%)。

结论：玻璃体腔注射bevacizumab的并发症少，安全性高。但需进一步的大样本、随机化、多中心的临床实验，规范该药的临床应用。

METHODS: Totally, 207 cases(207 eyes)with wet age-related macular degeneration were selected randomly. All cases were treated with intravitreal injections of bevacizumab(1.5mg/0.06mL)and asked for chief complaints at 1 day, 1 week, 4, 12 weeks after operation, and also examined for routine visual acuity(best corrected visual acuity, BCVA), non-contact tonometer, slit lamp microscope and indirect ophthalmoscope etc.

RESULTS: Among 207 cases(207 eyes), visual acuity improved efficiency was 90.8% 12 weeks after treatment, foreign body sensation was found in 7 cases(3.4%), eyelid skin pruritus in 1 case(0.5%), conjunctival congestion in 6 cases(2.9%), subconjunctival hemorrhage in 1 case(0.5%), post-operative intraocular pressure elevation in 2 cases(1.0%).

CONCLUSION: The intravitreal injection of bevacizumab is effective with fewer complications. We propose to carry out a further randomized multicenter and larger-sample clinical research and further draw up the clinical application criterion of bevacizumab.